Ocrelizumab is a pharmaceutical treatment developed for people with primary-progressive Multiple sclerosis (MS). It is an immunosuppressive drug that targets mature B cell lymphocytes which have the CD20 antibody on their surface. The therapy is similar to rituximab. Ocrelizumab is registered under the brand name Ocrevus, and on May 28, 2017, received approval by the U.S. Food and Drug Administration for treating MS.
Learn more[edit | edit source]
- 2017, After 40-year odyssey, first drug for aggressive MS wins FDA approval
- 2016, Wrapping Up Multiple Sclerosis
- 2016, New MS Drug Shows 'Breakthrough' Promise for Advanced Disease
See also[edit | edit source]
References[edit | edit source]
- FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
This article is a stub.
Please help improve this page if you can